BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22189054)

  • 1. Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer.
    Dienstmann R; De Dosso S; Felip E; Tabernero J
    Mol Oncol; 2012 Feb; 6(1):15-26. PubMed ID: 22189054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.
    Jeong WJ; Cha PH; Choi KY
    World J Gastroenterol; 2014 Aug; 20(29):9862-71. PubMed ID: 25110417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
    Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Research Progress of New Generation EGFR-TKIs after Third-generation].
    Liu Y; Li Y; Wang J
    Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):970-975. PubMed ID: 32773008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].
    Ni L; Nie L
    Zhongguo Fei Ai Za Zhi; 2018 Feb; 21(2):110-115. PubMed ID: 29526178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.
    Zhou J; Ji Q; Li Q
    J Exp Clin Cancer Res; 2021 Oct; 40(1):328. PubMed ID: 34663410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors.
    Liao BC; Lin CC; Lee JH; Yang JC
    J Biomed Sci; 2016 Dec; 23(1):86. PubMed ID: 27912760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
    Jotte RM; Spigel DR
    Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
    Ohashi K; Sequist LV; Arcila ME; Moran T; Chmielecki J; Lin YL; Pan Y; Wang L; de Stanchina E; Shien K; Aoe K; Toyooka S; Kiura K; Fernandez-Cuesta L; Fidias P; Yang JC; Miller VA; Riely GJ; Kris MG; Engelman JA; Vnencak-Jones CL; Dias-Santagata D; Ladanyi M; Pao W
    Proc Natl Acad Sci U S A; 2012 Jul; 109(31):E2127-33. PubMed ID: 22773810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
    Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
    Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology.
    Shah RR; Shah DR
    Drug Saf; 2019 Feb; 42(2):181-198. PubMed ID: 30649743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.
    Mukherji D; Spicer J
    Expert Opin Investig Drugs; 2009 Mar; 18(3):293-301. PubMed ID: 19243280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
    Nguyen KS; Kobayashi S; Costa DB
    Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research Progress of Targeted Therapy for EGFR Gene in Non-small Cell Lung Cancer].
    Zhang H; Zhang S
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):61-65. PubMed ID: 28103975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: Current status and future perspectives.
    Zhang YC; Zhou Q; Wu YL
    Cancer Lett; 2019 Sep; 459():240-247. PubMed ID: 31201840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
    Juchum M; Günther M; Laufer SA
    Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer.
    Tripathi SK; Pandey K; Rengasamy KRR; Biswal BK
    Med Res Rev; 2020 Nov; 40(6):2132-2176. PubMed ID: 32596830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.
    Ricordel C; Friboulet L; Facchinetti F; Soria JC
    Ann Oncol; 2018 Jan; 29(suppl_1):i28-i37. PubMed ID: 29462256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.